SCHEMBL696201

SCHEMBL696201

Cc1cc(N2C[C@H](S(C)(=O)=O)C[C@H]2C(=O)O)n(Cc2ccccc2)n1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AGTR2 P50052 3/20 0.53
SMYD3 Q9H7B4 2/20 0.41
KCNJ6 P48051 2/20 0.39
KCNJ5 P48544 2/20 0.39
KCNJ3 P48549 2/20 0.39
POLB P06746 1/20 0.37
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.36
PTGS2 P35354 1/20 0.35
S1PR1 P21453 1/20 0.35
S1PR5 Q9H228 1/20 0.35
GRN P28799 1/20 0.35
SORT1 Q99523 1/20 0.35
DPP4 P27487 1/20 0.35
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL696202 1.00 AGTR2 (0.53) AGTR2SMYD3KCNJ6KCNJ5KCNJ3
SCHEMBL695771 0.91 AGTR2 (0.44) AGTR2SMYD3KCNJ6KCNJ5KCNJ3
SCHEMBL696093 0.90 AGTR2 (0.46) AGTR2SMYD3KCNJ6KCNJ5KCNJ3
SCHEMBL696094 0.90 AGTR2 (0.46) AGTR2SMYD3KCNJ6KCNJ5KCNJ3
SCHEMBL696092 0.90 AGTR2 (0.46) AGTR2SMYD3KCNJ6KCNJ5KCNJ3
SCHEMBL696363 0.87 CTSS (0.49) AGTR2SMYD3KCNJ6KCNJ5KCNJ3
SCHEMBL696364 0.87 CTSS (0.49) AGTR2SMYD3KCNJ6KCNJ5KCNJ3
SCHEMBL695014 0.87 AGTR2 (0.49) AGTR2SMYD3KCNJ6KCNJ5KCNJ3
SCHEMBL695013 0.87 AGTR2 (0.49) AGTR2SMYD3KCNJ6KCNJ5KCNJ3
SCHEMBL695247 0.83 CTSS (0.53) AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP claimed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US claimed
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 AGTR2 317/4885SMYD3 4270/4885KCNJ6 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.